natgillin/translations-raw huggingface dataset:
Please tell your doctor or pharmacist if you or the child you are caring for:
Molimo obavijestite liječnika ili ljekarnika ako Vi ili dijete o kojem skrbite:
Please tell your doctor or pharmacist if you, or the child you are caring for:
Molimo obavijestite svog liječnika ili ljekarnika ako Vi ili dijete o kojem skrbite:
Please tell your doctor or pharmacist, if:
Obavijestite svog liječnika ili ljekarnika ako:
Please tell your doctor, if you are taking, have recently taken or might take any other medicines. (see also section “Warnings and precautions”).
Obavijestite svog liječnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove (pogledajte i dio "Upozorenja i mjere opreza").
Please tell your doctor, nurse or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Obavijestite svog liječnika, medicinsku sestru ili ljekarnika ako uzimate ili ste nedavno uzimali bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
Please tell your doctor, nurse or pharmacist if your child is taking or has recently taken any other medicines including medicines obtained without prescription or has recently received any other vaccine
Obavijestite svog liječnika, medicinsku sestru ili ljekarnika ako Vaše dijete uzima ili je nedavno uzimalo bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta, ili je nedavno primilo neko drugo cjepivo.
Please tell your doctor, or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ukoliko uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.
Please tell your doctor: if you have kidney problems.
Molimo obavijestite Vašeg liječnika ako: imate problema sa bubrezima.
Please tell your veterinary surgeon if your dog has any of these.
Molimo obavijestite vašeg veterinara ukoliko vaš pas ima nešto od navedenog.
Please turn the leaflet over for section 7.
Molimo pogledajte na drugoj strani Upute o lijeku dio 7.
Please use
Treba koristiti
Please use alternative capsule strength*
Treba koristiti drugu jačinu kapsula
Please use as follows: Subcutaneous use
Molimo primijenite na sljedeći način: Potkožno
Please verify you are using the correct dosage.
Molimo provjerite primjenjujete li točnu dozu.
Please write on the GONAL-f vial the day you prepared the solution.
Na bočicu s lijekom GONAL-f napišite datum pripreme otopine.
pleen
lezena
Plegridy 125 mcg injection
Plegridy 125 μg injekcija
Plegridy 125 micrograms solution for injection in pre-filled pen.
Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici.
Plegridy 125 micrograms solution for injection in pre-filled syringe.
Plegridy 125 mikrograma u otopini za injekciju u napunjenoj štrcaljki.
Plegridy 63 mcg injection Plegridy 94 mcg injection
Plegridy 63 μg injekcija Plegridy 94 μg injekcija
Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen
Plegridy 63 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 94 mikrograma otopina za injekciju u napunjenoj brizgalici
Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen Plegridy 125 micrograms solution for injection in pre-filled pen Peginterferon beta-1a
Plegridy 63 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 94 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon beta-1a
Plegridy 63 micrograms solution for injection in pre-filled pen.
Plegridy 63 mikrograma otopina za injekciju u napunjenoj brizgalici.
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe
Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe Plegridy 125 micrograms solution for injection in pre-filled syringe Peginterferon beta-1a
Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 125 mikrograma otopina za injekciju u napunjenoj štrcaljki peginterferon beta-1a
Plegridy 63 micrograms solution for injection in pre-filled syringe.
Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki.
Plegridy 94 micrograms solution for injection in pre-filled pen.
Plegridy 94 mikrograma otopina za injekciju u napunjenoj brizgalici.
Plegridy 94 micrograms solution for injection in pre-filled syringe.
Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki.
Plegridy also significantly reduced the risk of relapse by 39% (p=0.0003), the risk of sustained disability progression confirmed at 12 weeks by 38% (p=0.0383) and at 24 weeks (post-hoc analysis) by 54% (p=0.0069), the number of new or newly enlarging T2 lesions by 67% (p<0.0001), the number of Gd-enhancing lesions by 86% (p<0.0001) and the number of new T1
Plegridy je također značajno smanjio rizik od relapsa za 39% (p = 0,0003), rizik od kontinuirane progresije onesposobljenosti potvrđen nakon 12 tjedna za 38% (p=0,0383) i nakon 24 tjedna (post-hoc analiza) za 54% (p=0,0069), broj novih ili novo povećanih T2 lezija za 67% (p<0,0001), broj Gd pozitivnih lezija za 86% (p
Plegridy also significantly reduced the risk of relapse by 39% (p=0.0003), the risk of sustained disability progression confirmed at 12 weeks by 38% (p=0.0383) and at 24 weeks (post-hoc analysis) by 54% (p=0.0069), the number of new or newly enlarging T2 lesions by 67% (p<0.0001), the number of Gd-enhancing lesions by 86% (p<0.0001) and the number of new T1 hypointense lesions compared to placebo by 53% (p<0.0001).
Plegridy je također značajno smanjio rizik od relapsa za 39% (p = 0,0003), rizik od kontinuirane progresije onesposobljenosti potvrđen nakon 12 tjedna za 38% (p=0,0383) i nakon 24 tjedna (post-hoc analiza) za 54% (p=0,0069), broj novih ili novo povećanih T2 lezija za 67% (p<0,0001), broj Gd pozitivnih lezija za 86% (p <0,0001) i broj novih T1 hipointenzivnih lezija za 53% (p<0,0001) u usporedbi s placebom.
Plegridy binds to the type I interferon receptor on the surface of cells and elicits a cascade of intracellular events leading to the regulation of interferon-responsive gene expression.
Plegridy se veže na receptore interferona tipa I na površini stanica, te izaziva slijed intracelularnih zbivanja vodeći do ekspresije gena koje regulira interferon.
Plegridy can be kept outside a fridge at room temperature (up to 25°C) for up to 30 days but it must be kept away from light.
Plegridy se može čuvati izvan hladnjaka na sobnoj temperaturi (do 25 oC) do 30 dana, ali se mora čuvati zaštićen od svjetlosti.
Plegridy can be stored at room temperature (up to 25°C) for up to 30 days as long as it is stored away from light.
Plegridy se može čuvati na sobnoj temperaturi (do 25 oC) do 30 dana ukoliko se čuva zaštićen od svjetlosti.
Plegridy can be stored at room temperature (up to 25°C) for up to 30 days as long as it is stored away from light.
Plegridy se može čuvati na sobnoj temperaturi (do 25 oC) do 30 dana ukoliko se čuva zaštićenod svjetlosti.
Plegridy can be stored at room temperature (up to 25°C) for up to 30 days as long as it is stored away from light.
Plegridy se može čuvati na sobnoj temperaturi do 25 oC) do 30 dana ukoliko se čuva zaštićen od svjetlosti.
Plegridy can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating MS.
Plegridy se izdaje samo na liječnički recept, a liječenje treba započeti pod nadzorom liječnika koji ima iskustva u liječenju MS-a.
Plegridy continued to produce benefit in the second year of treatment.
Plegridy je nastavio stvarati koristi u drugoj godini liječenja.
Plegridy every 2 weeks significantly reduced the annualized relapse rate (ARR) by 36% compared to placebo (p=0.0007) at one year (Table 3) with consistent reductions of the ARR noted in subgroups defined by demographic and baseline disease characteristics.
Plegridy davan svaka 2 tjedna značajno je smanjio godišnju stopu relapsa (ARR) za 36% u odnosu na placebo (p = 0,0007) nakon jedne godine (tablica 3), s dosljednim smanjenjima ARR opaženim u podskupinama definiranim demografskim obilježjima i obilježjima bolesti na početku ispitivanja.
Plegridy every 2 weeks significantly reduced the annualized relapse rate (ARR) by 36% compared to placebo (p=0.0007) at one year (Table 3) with consistent reductions of the ARR noted in subgroups defined by demographic and baseline disease characteristics.
Plegridy davan svaka 2 tjedna značajno je smanjio godišnju stopu relapsa (ARR) za 36% u odnosu na placebo (p = 0,0007) nakon jedne godine (tablica 3), s dosljednim smanjenjima ARR opaženima u podskupinama definiranim demografskim i obilježjima bolesti na početku ispitivanja.
Plegridy has been shown to reduce the rate of relapses in patients with relapsing-remitting MS in a main study which lasted two years and involved 1,516 patients.
Dokazano je da Plegridy smanjuje broj relapsa u bolesnika oboljelih od relapsno-remitirajućeg oblika MS-a u glavnom ispitivanju koje je trajalo dvije godine i obuhvatilo je 1.516 bolesnika.
Plegridy is a clear and colourless solution for injection in a pre-filled pen.
Plegridy je bistra i bezbojna otopina za injekciju u napunjenoj brizgalici.
Plegridy is a clear and colourless solution for injection in a pre-filled syringe.
Plegridy je bistra i bezbojna otopina za injekciju u napunjenoj štrcaljki.
Plegridy is a medicine that contains the active substance peginterferon beta-1a.
Plegridy je lijek koji sadrži djelatnu tvar peginterferon beta-1a.
Plegridy is a single-use pen.
Plegridy je brizgalica za jednokratnu upotrebu.
Plegridy is an interferon beta-1a conjugated with a single, linear molecule of 20,000 Da methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde (20 kDa mPEG-O-2-methylpropionaldehyde) at a degree of substitution of 1 mole of polymer/mole of protein.
Plegridy je interferon beta-1a konjugiran s jednom, linearnom molekulom metoksi poli(etilenglikol)-O-2- metilpropionaldehida od 20 000 Da (20 kDa mPEG-O-2-metilpropionaldehid) sa stupnjem supstitucije od 1 mola polimera po molu proteina.
Plegridy is an interferon beta-1a conjugated with a single, linear molecule of 20,000 Da methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde (20 kDa mPEG-O-2-methylpropionaldehyde) at a degree of substitution of 1 mole of polymer/mole of protein.
Plegridy je interferon beta-1a konjugiran s jednom, linearnom molekulom metoksipoli(etilenglikol)-O-2- metilpropionaldehida od 20 000 Da (20 kDa mPEG-O-2-metilpropionaldehid) sa stupnjem supstitucije od 1 mola polimera po molu proteina.
Plegridy is available as a solution for injection in pre-filled pens or pre-filled syringes that contain 63, 94 or 125 micrograms peginterferon beta-1a.
Plegridy je dostupan kao otopina za injekciju u napunjenim aplikatorima ili napunjenim špricama koje sadrže 63, 94 ili 125 mikrograma peginterferon beta-1a.
Plegridy is given by injection under the skin of the abdomen, the arm or the thigh.
Plegridy se primjenjuje subkutanom injekcijom u abdomen, ruku ili bedro.
Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis (see section 5.1).
Plegridy je indiciran u odraslih bolesnika za liječenje relapsno remitirajućee multiple skleroze (vidjeti dio 5.1).
Plegridy is interferon beta-1a conjugated to a single, linear 20 kDa methoxy poly(ethyleneglycol) molecule at the alpha-amino group of the N-terminal amino acid residue.
Plegridy je interferon beta-1a konjugiran s jednom, linearnom molekulom metoksipoli (etilenglikola) od 20 kDa na alfa-amino skupini N-terminalnog kraja aminokiseline.
Plegridy is not to be used in children and adolescents below 18 years old.
Plegridy se ne smije koristiti u djece i adolescenata ispod 18 godina starosti.
Plegridy may make you feel sick (see section 4 “Possible side effects”).
Zbog Plegridyja možete osjećati mučninu (pogledajte dio 4 "Moguće nuspojave").
Plegridy must not be used in patients who are currently suffering from severe depression or have thoughts of suicide.
Plegridy se ne smije koristiti u bolesnika koji trenutno boluju od ozbiljne depresije ili pomišljaju na samoubojstvo.
Plegridy pen Initiation Pack contains your first two injections to gradually adjust your dose.
Početno pakiranje s Plegridy brizgalicama sadrži Vaše prve dvije injekcije za postupno podešavanje doze.
Plegridy pen is for injection under the skin (subcutaneous injection).
Plegridy brizgalica je namijenjena za injekciju pod kožu (potkožnu injekciju).
Plegridy pen should be injected into the thigh, abdomen or back of the upper arm.
Plegridy brizgalicu treba injicirati u bedro, trbuh ili stražnji dio nadlaktice.
Plegridy pen will “click” several times.
Plegridy brizgalica se oglasi zvukom “klik” nekoliko puta.
Plegridy pre-filled pen must not be used if the liquid is coloured, cloudy, or contains floating particles.
Plegridy u napunjenoj brizgalici se ne smije koristiti ako je tekućina obojena, zamućena ili ako sadrži plutajuće čestice.
Plegridy pre-filled pen must not be used unless green stripes are visible in the Plegridy pre-filled pen injection status window.
Plegridy u napunjenoj brizgalici se ne smije koristiti ukoliko zelene trake nisu vidljive u prozorčiću statusa injekcije u napunjenoj brizgalici.
Plegridy pre-filled syringe Initiation Pack contains your first two injections to gradually adjust your dose.
Početno pakiranje Plegridyja s napunjenenim štrcaljkama sadrži Vaše prve dvije injekcije za postupno podešavanje doze.
Plegridy pre-filled syringe is for injection under the skin (subcutaneous injection).
Plegridy u napunjenoj štrcaljki je namijenjen za injekciju pod kožu (potkožnu injekciju).
Plegridy pre-filled syringe must not be used if the liquid is coloured, cloudy, or contains floating particles.
Plegridy u napunjenoj štrcaljki se ne smije koristiti ako je tekućina obojena, zamućena ili ako sadrži plutajuće čestice.
Plegridy pre-filled syringe should be injected into the thigh, abdomen or back of the upper arm.
Plegridy u napunjenoj štrcaljki treba injicirati u bedro, trbuh ili stražnji dio nadlaktice.
Plegridy seems to work by stopping the body’s immune system from damaging your brain and spinal cord.
Čini se da Plegridy djeluje tako što sprječava imunološki sustav tijela da ošteti Vaš mozak i leđnu moždinu.
Plegridy should be used carefully with medicines that are broken down in the body by a group of proteins called “cytochrome P450” (e.g. some medicines used for epilepsy or depression).
Plegridy treba oprezno koristiti s lijekovima koje u tijelu razgrađuje skupina proteina pod nazivom "citokrokrom P450" (npr. neki lijekovi koji se koriste za epilepsiju ili depresiju).
Plenadren 20 mg modified-release tablets
Plenadren 20 mg tablete s prilagođenim oslobađanjem
Plenadren 20 mg modified-release tablets EU/1/11/715/002
Plenadren 20 mg tablete s prilagođenim oslobađanjem EU/1/11/715/002
Plenadren 20 mg modified-release tablets hydrocortisone
Plenadren 20 mg tablete s prilagođenim oslobađanjem hidrokortizon
Plenadren 5 mg modified-release tablets
Plenadren 5 mg tablete s prilagođenim oslobađanjem
Plenadren 5 mg modified-release tablets EU/1/11/715/001
Plenadren 5 mg tablete s prilagođenim oslobađanjem EU/1/11/715/001
Plenadren 5 mg modified-release tablets hydrocortisone
Plenadren 5 mg tablete s prilagođenim oslobađanjem hidrokortizon
Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets
Plenadren 5 mg tablete s prilagođenim oslobađanjem Plenadren 20 mg tablete s prilagođenim oslobađanjem
Plenadren can be used during breast-feeding.
Plenadren se može primjenjivati u razdoblju dojenja.
Plenadren can be used during pregnancy.
Plenadren se može primjenjivati u trudnoći.
Plenadren is given as maintenance therapy.
Plenadren se daje kao terapija održavanja.
Plenadren with food and drink
Plenadren s hranom i pićem
Plerixafor inhibited tumour growth in in vivo models of non-Hodgkin’s lymphoma, glioblastoma, medulloblastoma, and acute lymphoblastic leukaemia when dosed intermittently.
Pri intermitentnom doziranju pleriksafor je inhibirao rast tumora u in vivo modelima ne-Hodgkinova limfoma, glioblastoma, meduloblastoma i akutne limfoblastične leukemije.
Plerixafor is a bicyclam derivative, a selective reversible antagonist of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1 (SDF-1), also known as CXCL12.
Pleriksafor je derivat biciklama, selektivni reverzibilni antagonist kemokinskog receptora CXCR4 koji blokira vezanje njemu srodnog liganda, iz stromalnih stanica dobivenog čimbenika-1α (engl. stromal cell- derived factor-1α, SDF-1α) poznatog i kao CXCL12.
Plerixafor is moderately bound to human plasma proteins up to 58%.
Pleriksafor se umjereno veže za ljudske proteine u plazmi, do 58%.
Plerixafor is not metabolised in vitro using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug-metabolising CYP450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5).
Pleriksafor se in vitro ne metabolizira preko ljudskih jetrenih mikrosoma niti ljudskih primarnih hepatocita te ne iskazuje inhibicijsko djelovanje in vitro prema enzimima CYP450 (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 i 3A4/5) koji metaboliziraju većinu lijekova.
Pleural and pericardial effusions, regardless of causality, occurred in 2% and <1% of patients, respectively, receiving Tasigna 300 mg twice daily.
Pleuralni, odnosno perikardijalni izljevi, neovisno o uzroku, pojavili su se u 2%, odnosno <1% bolesnika liječenih Tasignom 300 mg dva puta na dan.
Pleural cavity
Pleuralna šupljina
pleural effusion (abnormal collection of fluid in the pleural space)
pleuralna efuzija (abnormalno nakupljanje tekućine u pleuralnom prostoru)
pleural effusion (abnormal collection of fluid in the pleural space);
pleuralna efuzija (abnormalno nakupljanje tekućine u pleuralnom prostoru),
pleural effusion (abnormal collection of fluid on the pleural space);
pleuralna efuzija (abnormalno nakupljanje tekućine u pleuralnom prostoru),
Pleural effusion Dyspnoea †
pleuralni izljev dispneja
Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
Pleuralni izljev je češće zabilježen u bolesnika s GIST-om i u bolesnika s transformiranim KML-om (KML-ubrzana faza i KML-blastična kriza), nego u bolesnika s kroničnim KML-om.
pleural effusion*, dyspnoea
pleuralni izljev*, dispneja
pleural effusion, dyspnoea
pleuralni izljev, dispneja u naporu, faringolaringealn a bol
Pleural effusion, dyspnoea, cough
pleuralni izljev, dispneja, kašalj
Pleural effusion, Exacerbated Dyspnoea, Productive cough, Haemoptysis, Wheezing, Epistaxis, Exertional dyspnoea, Sinus congestion, Nasal congestion, Pharyngolaryngeal pain
Pleuralni izljev, Pogoršanje dispneje, Produktivni kašalj, Hemoptiza, Piskanje, Epistaksa, Dispneja u naporu, Začepljenje sinusa, Začepljenje nosa, Faringolaringealna bol
Pleural effusion, pneumonitis, rhinorrhoea
Pleuralni izljev, pneumonitis, curenje iz nosa
pleural effusion1)
pleuralna efuzija1)
Pleural effusiona,b
pleuralni izljeva,b
Pleural fibrosis*, orthopnoea, respiratory failure
pleuralna fibroza*, ortopneja, zatajenje disanja
Pleuritic pain
bolovi u pleuri
Pleuritic pain*, pulmonary embolism*, dry throat, dysphonia, increased upper airway secretion, oropharyngeal blistering
pleuralna bol*, plućna embolija*, suho grlo, disfonija, pojačana sekrecija gornjih dišnih putova, mjehurići u ustima i ždrijelu
PlGF can synergize with VEGF- A in these processes, and is also known to promote leucocyte infiltration and vascular inflammation.
PlGF može sinergistički djelovati s VEGF-A u ovim procesima, a zna se i da potiče inflitraciju leukocitima i upalu krvnih žila.
PLIVA Croatia Ltd
PLIVA Hrvatska d.o.o.
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.), Prilaz baruna Filipovića 25, 10000 Zagreb, Croatia
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.), Prilaz baruna Filipovića 25, 10000 Zagreb, Hrvatska
Plum
Boja šljive
Plunger
Klip
Plunger rod
Klip
Plunger rod
Potisni klip
Plunger rod for pre-filled sterile water syringe x1
Klip za napunjenu štrcaljku sa sterilnom vodom x1
Plunger rods Vial adapters
Klipovi štrcaljke Nastavci za bočice
Plunger Syringe tip
Klip Vršak štrcaljke
plus telaprevir.
ritonavirom uz telaprevir.
PML cases have occurred with Tecfidera and other products containing fumarates in the setting of moderate to severe prolonged lymphopenia.
Slučajevi PML-a pojavili su se tijekom primjene Tecfidere i drugih lijekova koji sadrže fumarate u stanju umjerene do teške i produljene limfopenije.
PML has been reported in patients treated with Gazyvaro (see section 4.4).
U bolesnika liječenih lijekom Gazyvaro prijavljen je PML (vidjeti dio 4.4).
PML has occurred in the setting of moderate to severe prolonged lymphopenia (please refer to section 4.4).
PML se pojavio u uvjetima umjerene do teške i produljene limfopenije (pogledajte dio 4.4).
PML has symptoms that may be similar to those of an MS attack, and can lead to severe disability or death.
Simptomi PML-a, koji može uzrokovati teški invaliditet ili smrtni ishod, mogu biti slični simptomima napadaja povezanog s multiplom sklerozom.
PML is a very rare and life-threatening brain infection that has been reported in very few patients having treatment with Gazyvaro.
PML je vrlo rijetka i po život opasna infekcija mozga prijavljena kod primjene lijeka Gazyvaro.
PML is a very rare and life-threatening brain infection that has been reported with Gazyvaro.
PML je vrlo rijetka i po život opasna infekcija mozga prijavljena kod primjene lijeka Gazyvaro.
PML is an opportunistic infection caused by John- Cunningham virus (JCV), which may be fatal or result in severe disability.
PML je oportunistička infekcija uzrokovana John- Cunningham virusom (JCV), koja može biti smrtonosna ili uzrokovati tešku invalidnost.
Pneumococcal immune responses were compared using non-inferiority criteria, including the percentage of subjects with serum anti-polysaccharide serotype-specific IgG concentration
Imunološki odgovori na pneumokok uspoređeni su pomoću mjera neinferiornosti koje su uključivale postotak ispitanika s koncentracijom serumskog antipolisaharidnog IgG specifičnog za serotip od
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Cjepivo protiv pneumokoka, polisaharidno, konjugirano (13-valentno, adsorbirano)
Pneumococcal polysaccharide conjugate vaccine (adsorbed)
Polisaharidno, konjugirano cjepivo protiv pneumokoka (adsorbirano)
Pneumococcal polysaccharide serotype 11 2.2 µg
Pneumokokni polisaharid serotipa 11 2,2 µg
Pneumococcal polysaccharide serotype 11,2 1 microgram
Pneumokokni polisaharid serotipa 11,2 1 mikrogram
Pneumococcal polysaccharide serotype 141 2.2 µg
Pneumokokni polisaharid serotipa 141 2,2 µg
Pneumococcal polysaccharide serotype 141,2 1 microgram
Pneumokokni polisaharid serotipa 141,2 1 mikrogram
Pneumococcal polysaccharide serotype 18C1 2.2 µg
Pneumokokni polisaharid serotipa 18C1 2,2 µg
Pneumococcal polysaccharide serotype 18C1,3 3 micrograms
Pneumokokni polisaharid serotipa 18C1,3 3 mikrograma
Pneumococcal polysaccharide serotype 19A1 2.2 µg
Pneumokokni polisaharid serotipa 19A1 2,2 µg
Pneumococcal polysaccharide serotype 19F1 2.2 µg
Pneumokokni polisaharid serotipa 19F1 2,2 µg
Pneumococcal polysaccharide serotype 19F1,4 3 micrograms
Pneumokokni polisaharid serotipa 19F1,4 3 mikrograma
Pneumococcal polysaccharide serotype 23F1,2 1 microgram
Pneumokokni polisaharid serotipa 23F1,2 1 mikrogram
Pneumococcal polysaccharide serotype 31 2.2 µg
Pneumokokni polisaharid serotipa 31 2,2 µg
Pneumococcal polysaccharide serotype 41 2.2 µg
Pneumokokni polisaharid serotipa 41 2,2 µg
Pneumococcal polysaccharide serotype 41,2 3 micrograms
Pneumokokni polisaharid serotipa 41,2 3 mikrograma
Pneumococcal polysaccharide serotype 51 2.2 µg
Pneumokokni polisaharid serotipa 51 2,2 µg